News 

About IAPACEducationAdvocacyConferencesWhat's NewPublicationsJoin IAPACContact UsSearchLinksMain Page
 

Norvir Advisory

About the IAPAC Norvir Advisory

Q. What is the IAPAC Norvir Advisory?

A. The IAPAC Norvir Advisory is a cyberspace publication of the International Association of Physicians in AIDS Care (IAPAC) developed primarily for physicians who have patients on antiviral therapy that includes Norvir (ritonavir) capsules and who may have questions about switching these patients to Norvir liquid of to another antiviral drug/regimen.

Q. Why would patients have to switch from Norvir capsules to Norvir liquid?

A. Refer to the Abbott News Release Abbott Announces Difficulty Manufacturing Norvir (Ritonavir) Capsules.

Q. Why is IAPAC providing this information rather than Abbott?

A. IAPAC is providing this information to physicians and other concerned individuals in addition to the information provided by Abbott on their Web site.

The IAPAC Norvir Advisory provides an independent evaluation and assessment of many of the issues involved in any change of antiviral therapy, including changes in the Norvir formulary as well as changes in antiviral therapy.

The IAPAC Norvir Advisory provides answers to questions raised by physicians. The answers are provided by their peers based on clinical experience. The IAPAC Norvir Advisory is parallel to a "second opinion." Abbott and all other pharmaceutical companies may be able to answer specific questions about the drugs they manufacture based on data they have. However, the companies are prohibited from making recommendations on other therapeutic regimens. Also, there may be a difference in the response to some questions based on physiciansí experience which may not be reflected in some of the data upon which a pharmaceutical company relies to provide answers.

Q. Who manages the IAPAC Norvir Advisory?

A. These are the members of the ad hoc IAPAC Norvir Advisory Committee:

 
Committee Chair
 
Charles Farthing, MD
Medical Director
AIDS Healthcare Foundation
8631 W 3rd Street, Suite 740E
Los Angeles, CA 90048
Phone (310)-657-9353, (213)-662-0430 Fax: (310)-657-9367
 
Committee Members
 
Eric Archibeque, MD
Medical Director, Statdlanders Pharmacy;
Assistant Clinical Professor of Medicine
University of California, San Francisco School of Medicine
65 Norfolk Street
San Francisco, CA 94103
Ottawa, ON K1H 8L6 Canada
Phone (415)-626-1820, Fax: (415)-626-1819
 
William Cameron, MD, FRCPC
Associate Professor of Medicine
Ottawa General Hospital
501 Smyth Road, Room G12
Ottawa, ON K1H 8L6 Canada
Phone: (613)-737-8880/8923 Fax: (613)-737-8682
 
Calvin Cohen, MD
Research Director
CRI of New England
320 Washington Street
Brookline, MA 02146
Phone: (617) 566-4004 ext. 11 Fax: (617) 566-8226
 
Eric Daar, MD
Department of Infectious Diseases
Cedar Sinai Medical Hospital
8700 Beverly Blvd., Suite B217
Los Angeles, CA 90048
Phone: (310)-855-3896 Fax: (310)-659-9741
 
Sven Danner, MD
Universteit van Amsterdam
Academisch Medisch Centrum
Meibergdreff 9
1105 AZ Amsterdam Zuidoost
Netherlands
Phone: 011-31-20-5664380 Fax: 011-31-6963271
 
Joel Gallant, MD
Infectious Diseases
John Hopkins Hospital
600 N Wolf
Baltimore, MD 21287
Phone (410)-955-1754 Fax: (410)-955-0740
 
Lisa Hirschhorn, MD
DIMOCK Health Center
55 Dimock St.
Roxbury, MA 02199
Phone (617)-442-8800 Fax: (617)-442-1702
 
Vincent Jarvis, MD
Internal Medicine
So Be Well, Inc.
1680 Michigan Avenue, Suite 820
Miami Beach, FL 33139
Phone: (305)-673-8833 Fax: (310)-673-8975
 
Mark Kline, MD
Professor of Medicine
Texas Children's Hospital
Baylor College of Medicine
6621 Frannin Street, MC 1-3291
Houston, TX 77030-2399
Phone: (713) 770-1038 Fax: (713) 770-1281
 
Joep Lange, MA - MD, Ph.D.
Division of Infectious Diseases
University of Amsterdam
Meibergdreef 9
1105 AZ Amsterdam, Netherlands
Phone: 011-31-20-566-4479 Fax: 011-31-20-691-8821
 
Stefan Mauss, MD
Adelheidstr. 18, 80798
Munich
Germany
Phone: 011-49-89-558-180 Fax: 011-49-8955-03941
Phone: 011-49-211-348517 Fax: 011-49-8955-03941
 
David Paar, MD
Department of Internal Medicine
University of Texas
4.140 McCullough Bldg. G-65 301 University
Galveston, TX 77555-0765
Phone: (409)-747-0243 Fax: (409)-772-6527
 
Richard Parker, MD
Associate Professor, Infectious Diseases
1160 Varnum Street NE, Suite 317
Washington, DC 20017
Phone: (202)-529-7933 Fax: (202)-529-1964
 
Praphan Phanuphak, MD, Ph.D.
Thai Red Cross Society Program on AIDS
Faculty of Medicine, Chulalongkorn University
1871 Rama IV Road, Bangkok, 10330, Thailand
Phone: 011-662-245-2323 Fax: 011-662-254-7577
 
Peter Ruane, MD
Tower Infectious Disease Medical Association
8631 W 3rd Street
Los Angeles, CA 90048
Phone: (310)-358-2300 Fax: (310)-358-2323
 
James F. Stanford, MD
Associate Professor, Infectious Diseases
UMKC School of Medicine
2411 Holmes Street
Kansas City, MO 64108-2792
Phone: (816)-235-1915 Fax: (816)-235-5174

Q. Are there any people with HIV disease on the IAPAC Norvir Advisory Committee?

A. IAPAC does not solicit information about committee membersí health status. There was no specific recruitment of HIV-infected patients to serve on a committee that is primarily charged with developing information for physicians. However, representatives of AIDS Service Organizations (ASOs) who are affiliate members of IAPAC will serve on the IAPAC Norvir Advisory Committee. The members are charged with making recommendations about information that may be helpful to the thousands of ASOs worldwide who provide services to people with HIV disease, many of which are on Norvir therapy.

Q. Is the information in the IAPAC Norvir Advisory peer-reviewed?

A. Not in the traditional form of peer review. The urgency of developing this resource and the information available through this resource makes it impossible to follow the standard of method of peer review which for each of the items might normally take weeks or months to complete such review and editing.

Instead, each IAPAC Norvir Advisory Committee member is provided access to a private developmental committee section on the IAPAC Web site which will feature the information scheduled to be uploaded to the IAPAC Norvir Advisory section on the IAPAC Web site. Each member is given 48 hours to offer comments to Dr. Farthing about the scheduled information. These comments are reviewed by Dr. Farthing, who has the option of conferring with the author of the information for possible editorial changes. Any dissenting comments and the reasons for the dissent along with the committee memberís name will be featured after each general entry. This system at least provides for time-sensitive review and comments from those members who have the opportunity of reviewing the data.

Q. How does IAPAC provide this information to physicians and other concerned individuals who do not have access to the Internet?

A. IAPAC will provide the IAPAC Norvir Advisory by fax or by mail to any physician who has patients on Norvir, any pharmacist from whom patients on Norvir capsules may be seeking information, and any ASO whose clients may be seeking similar information, and who do not have access to the Internet or who, for other reasons, may not be able to access the IAPAC Web site. The link to this information is here.

Q. Is the IAPAC Norvir Advisory available in languages other than English?

A. IAPAC is committed to providing translations of the IAPAC Norvir Advisory in any language necessary to inform the physicians, pharmacists, and ASOs who need this information for their patients and clients. IAPAC welcomes recommendations on experienced medical translators in all languages, in particular those who may possess HTML experience.

Q. How is the IAPAC Norvir Advisory funded?

A. The IAPAC Norvir Advisory is funded through an unrestricted educational grant from Abbott. The IAPAC Norvir Advisory is independent of Abbott, and designed to allow physicians who have experience in conducting clinical trials with Norvir and/or prescribing Norvir to their patients to offer their personal experience in commenting on various topics as well as answering specific questions posed by their peers. The independence of the members of the IAPAC Norvir Advisory Committee is a condition of membership.

Posted 9/2/98